1
|
Goupil E, Lacroix L, Brière J, Guga S, Saba-El-Leil MK, Meloche S, Labbé JC. OSGN-1 is a conserved flavin-containing monooxygenase required to stabilize the intercellular bridge in late cytokinesis. Proc Natl Acad Sci U S A 2024; 121:e2308570121. [PMID: 38442170 PMCID: PMC10945809 DOI: 10.1073/pnas.2308570121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Accepted: 01/24/2024] [Indexed: 03/07/2024] Open
Abstract
Cytokinesis is the last step of cell division and is regulated by the small GTPase RhoA. RhoA activity is required for all steps of cytokinesis, including prior to abscission when daughter cells are ultimately physically separated. Like germ cells in all animals, the Caenorhabditis elegans embryonic germline founder cell initiates cytokinesis but does not complete abscission, leaving a stable intercellular bridge between the two daughter cells. Here, we identify and characterize C. elegans OSGN-1 as a cytokinetic regulator that promotes RhoA activity during late cytokinesis. Sequence analyses and biochemical reconstitutions reveal that OSGN-1 is a flavin-containing monooxygenase (MO). Genetic analyses indicate that the MO activity of OSGN-1 is required to maintain active RhoA at the end of cytokinesis in the germline founder cell and to stabilize the intercellular bridge. Deletion of OSGIN1 in human cells results in an increase in binucleation as a result of cytokinetic furrow regression, and this phenotype can be rescued by expressing a catalytically active form of C. elegans OSGN-1, indicating that OSGN-1 and OSGIN1 are functional orthologs. We propose that OSGN-1 and OSGIN1 are conserved MO enzymes required to maintain RhoA activity at the intercellular bridge during late cytokinesis and thus favor its stability, enabling proper abscission in human cells and bridge stabilization in C. elegans germ cells.
Collapse
Affiliation(s)
- Eugénie Goupil
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QCH3C 3J7, Canada
| | - Léa Lacroix
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QCH3C 3J7, Canada
| | - Jonathan Brière
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QCH3C 3J7, Canada
| | - Sandra Guga
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QCH3C 3J7, Canada
| | - Marc K. Saba-El-Leil
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QCH3C 3J7, Canada
| | - Sylvain Meloche
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QCH3C 3J7, Canada
- Department of Pharmacology and Physiology, Université de Montréal, Montréal, QCH3C 3J7, Canada
| | - Jean-Claude Labbé
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QCH3C 3J7, Canada
- Department of Pathology and Cell Biology, Université de Montréal, Montréal, QCH3C 3J7, Canada
| |
Collapse
|
2
|
Sharma S, Kohli N, Brière J, Nabki F, Ménard M. Integrated 1 × 3 MEMS silicon nitride photonics switch. Opt Express 2022; 30:22200-22220. [PMID: 36224924 DOI: 10.1364/oe.460533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2022] [Accepted: 05/23/2022] [Indexed: 06/16/2023]
Abstract
We present a 1 × 3 optical switch based on a translational microelectromechanical system (MEMS) platform with integrated silicon nitride (SiN) photonic waveguides. The fabricated devices demonstrate efficient optical signal transmission between fixed and suspended movable waveguides. We report a minimum average insertion loss of 4.64 dB and a maximum average insertion loss of 5.83 dB in different switching positions over a wavelength range of 1530 nm to 1580 nm. The unique gap closing mechanism reduces the average insertion loss across two air gaps by a maximum of 7.89 dB. The optical switch was fabricated using a custom microfabrication process developed by AEPONYX Inc. This microfabrication process integrates SiN waveguides with silicon-on-insulator based MEMS devices with minimal stress related deformation of the MEMS platform.
Collapse
|
3
|
Brière J, Gadegbeku B, Amoros E, Charbotel B. Surveillance des accidents corporels de la circulation routière liés au travail en France, années 2014 et 2015. ARCH MAL PROF ENVIRO 2020. [DOI: 10.1016/j.admp.2019.12.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
4
|
Sharma S, Kohli N, Brière J, Ménard M, Nabki F. Translational MEMS Platform for Planar Optical Switching Fabrics. Micromachines (Basel) 2019; 10:mi10070435. [PMID: 31262085 PMCID: PMC6680699 DOI: 10.3390/mi10070435] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 06/26/2019] [Accepted: 06/29/2019] [Indexed: 12/03/2022]
Abstract
While 3-D microelectromechanical systems (MEMS) allow switching between a large number of ports in optical telecommunication networks, the development of such systems often suffers from design, fabrication and packaging constraints due to the complex structures, the wafer bonding processes involved, and the tight alignment tolerances between different components. In this work, we present a 2-D translational MEMS platform capable of highly efficient planar optical switching through integration with silicon nitride (SiN) based optical waveguides. The discrete lateral displacement provided by simple parallel plate actuators on opposite sides of the central platform enables switching between different input and output waveguides. The proposed structure can displace the central platform by 3.37 µm in two directions at an actuation voltage of 65 V. Additionally, the parallel plate actuator designed for closing completely the 4.26 µm air gap between the fixed and moving waveguides operates at just 50 V. Eigenmode expansion analysis shows over 99% butt-coupling efficiency the between the SiN waveguides when the gap is closed. Also, 2.5 finite-difference time-domain analysis demonstrates zero cross talk between two parallel SiN waveguides across the length of the platform for a 3.5 µm separation between adjacent waveguides enabling multiple waveguide configuration onto the platform. Different MEMS designs were simulated using static structural analysis in ANSYS. These designs were fabricated with a custom process by AEPONYX Inc. (Montreal, QC, Canada) and through the PiezoMUMPs process of MEMSCAP (Durham, NC, USA).
Collapse
Affiliation(s)
- Suraj Sharma
- Department of Electrical Engineering, Ecole de Technologie Supérieure, Montréal, QC H3C 1K3, Canada.
| | - Niharika Kohli
- Department of Electrical Engineering, Ecole de Technologie Supérieure, Montréal, QC H3C 1K3, Canada
| | | | - Michaël Ménard
- Department of Computer Science, Université du Québec à Montreal, Montréal, QC H2X 3Y7, Canada
| | - Frederic Nabki
- Department of Electrical Engineering, Ecole de Technologie Supérieure, Montréal, QC H3C 1K3, Canada
| |
Collapse
|
5
|
Bossard C, Laghmari O, Le Bris Y, Bonnet A, Moreau A, El Alami Thomas W, Pavageau A, Guerzider P, Maisonneuve H, Ruminy P, Bene M, Casasnovas O, Canioni D, Thieblemont C, Petrella T, Jardin F, Salles G, Tilly H, Gaulard P, Haioun C, Brière J, Le Gouill S, Copie Bergman C, Molina T. REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE. Hematol Oncol 2019. [DOI: 10.1002/hon.11_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Bossard
- Department of Pathology; University Hospital of Nantes; Nantes France
| | - O. Laghmari
- Department of Pathology; University Hospital of Nantes; Nantes France
| | - Y. Le Bris
- Department of Hematology Biology; University Hospital of Nantes; Nantes France
| | - A. Bonnet
- Department of Hematology; University Hospital of Nantes; Nantes France
| | - A. Moreau
- Department of Pathology; University Hospital of Nantes; Nantes France
| | | | - A. Pavageau
- Department of Pathology; Centre Hospitalier de la Roche sur Yon; La Roche sur Yon France
| | - P. Guerzider
- Department of Pathology; Centre Hospitalier de Saint Nazaire; Saint Nazaire France
| | - H. Maisonneuve
- Department of Hematology; Centre Hospitalier de la Roche sur Yon; La Roche sur Yon France
| | - P. Ruminy
- INSERM U918; Centre Henri Becquerel; Rouen France
| | - M. Bene
- Department of Hematology Biology; University Hospital of Nantes; Nantes France
| | - O. Casasnovas
- Department of Hematology; University Hospital; Dijon France
| | - D. Canioni
- Department of Pathology; Hopital Necker Enfants Malades; Paris France
| | - C. Thieblemont
- Hemato-oncology Department; Hopital Saint Louis; Paris France
| | - T. Petrella
- Department of Medical Oncology; Odette Cancer Center; Toronto Canada
| | - F. Jardin
- Department of Hematology; Centre Henri Becquerel; Rouen France
| | - G. Salles
- Department of Hematology; Hospice Civils de Lyon; Lyon France
| | - H. Tilly
- Department of Hematology; Centre Henri Becquerel; Rouen France
| | - P. Gaulard
- Department of Pathology; Groupe Hospitalier Henri Mondor; Creteil France
| | - C. Haioun
- Department of Hematology; Groupe Hospitalier Henri Mondor; Creteil France
| | - J. Brière
- Hemato-oncology Department; Hopital Saint Louis; Paris France
| | - S. Le Gouill
- Department of Hematology; University Hospital of Nantes; Nantes France
| | - C. Copie Bergman
- Department of Pathology; Groupe Hospitalier Henri Mondor; Creteil France
| | - T.J. Molina
- Department of Pathology; Hopital Necker Enfants Malades; Paris France
| |
Collapse
|
6
|
Petrella T, Copie-Bergman C, Brière J, Delarue R, Jardin F, Ruminy P, Thieblemont C, Figeac M, Canioni D, Feugier P, Fabiani B, Leroy K, Parrens M, André M, Haioun C, Salles GA, Gaulard P, Tilly H, Jais JP, Molina TJ. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. Ann Oncol 2018; 28:1042-1049. [PMID: 28327893 DOI: 10.1093/annonc/mdx022] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Background Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk factors in elderly patients treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP), maintain their prognostic value in a large prospective clinical trial. Patients and methods We evaluated 285 paraffin-embedded samples from patients (60-80 years of age) enrolled in the Lymphoma Study Association trial LNH03-6B who were treated with R-CHOP. We correlated the COO defined by the transcriptome according to the Wright algorithm with that defined by the Hans algorithm in a subset of 62 tumors with available frozen tissue samples. Results The non-germinal center B-cell-like phenotype according to the Hans algorithm and BCL2 expression (but not MYC and BCL2 coexpression) predicted worse progression-free survival [hazard ratio (HR)=1.78, P = 0.003 and HR = 1.79, P = 0.003, respectively] and overall survival (HR = 1.85, P = 0.005 and HR = 1.67, P = 0.02, respectively) independently of the International Prognostic Index. The correlation between the Hans algorithm and the Wright algorithm was 91%, with an almost perfect concordance according to a kappa test (0.81). Conclusions Our results suggest that immunohistochemically defined COO remains a useful tool for predicting prognosis in diffuse large B-cell lymphoma when performed under optimized standardized conditions and that BCL2 expression may help to identify elderly patients at risk for relapse and who could potentially respond to anti-BCL2 targeted agents. In this prospective phase III trial, the coexpression of MYC and BCL2 does not appear to predict worse survival. Clinical trial Number NCT00144755.
Collapse
Affiliation(s)
| | - C Copie-Bergman
- Pathology, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil and IMRB, INSERM U955 Unité, Créteil
| | - J Brière
- Pathology, AP-HP, Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - R Delarue
- Hematology, AP-HP, Necker Enfants-Malades, Paris
| | - F Jardin
- Hematology and UMR918, Centre Henri Becquerel, Université de Rouen, Rouen
| | - P Ruminy
- Hematology and UMR918, Centre Henri Becquerel, Université de Rouen, Rouen
| | - C Thieblemont
- Hemato-Oncology, AP-HP, Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité and EA 7324, Paris Descartes, Sorbonne Paris Cité, Paris
| | - M Figeac
- Functional Genomic Platform, Cancer Research Institute, Lille
| | - D Canioni
- Pathology, AP-HP, Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris
| | | | - B Fabiani
- Pathology, AP-HP, Saint-Antoine, Paris
| | - K Leroy
- Pathology, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil and IMRB, INSERM U955 Unité, Créteil
| | - M Parrens
- Pathology, CHU Bordeaux, Inserm U1053, Bordeaux, France
| | - M André
- Hematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
| | - C Haioun
- Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil
| | - G A Salles
- Haematology, Hospices Civils de Lyon, Université Claude Bernard, Pierre Bénite
| | - P Gaulard
- Pathology, AP-HP, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Université Paris-Est Créteil, Créteil and IMRB, INSERM U955 Unité, Créteil
| | - H Tilly
- Hematology and UMR918, Centre Henri Becquerel, Université de Rouen, Rouen
| | - J P Jais
- Biostatistics, AP-HP, Necker Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, Paris
| | - T J Molina
- Pathology, AP-HP, Necker, Université Paris Descartes, Sorbonne Paris Cité, Paris.,EA7324, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
7
|
Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 2016; 51:51-7. [PMID: 26367239 DOI: 10.1038/bmt.2015.213] [Citation(s) in RCA: 187] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 07/31/2015] [Indexed: 01/21/2023]
Abstract
Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.
Collapse
Affiliation(s)
| | - N Schmitz
- AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany
| | | | - D Gill
- Princess Alexandra Hospital, Woodville, SA, Australia
| | - D Linch
- University College London, Cancer Institute, London, UK
| | - M Trneny
- Charles Univ. General Hosp., Praha, Czech Republic
| | - N Milpied
- Hématologie Clinique et thérapie cellulaire, Hôpital Haut-Lévêque, Pessac, France
| | - J Radford
- University of Manchester, c/o Department of Medical Oncology, Christie Hospital NHS, Manchester, UK
| | - N Ketterer
- Clinique Bois-Cerf, Lausanne, Switzerland
| | | | - U Dührsen
- Universitätsklinikum Essen, KlinikfürHämatologie, Essen, Germany
| | - D Ma
- St Vincent's Hospital Sydney, Darlinghurst, NW, Australia
| | - J Brière
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| | - C Thieblemont
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| | - G Salles
- Hospices Civils de Lyon, Service d'Hématologie, Université de Lyon, Lyon, France
| | - C H Moskowitz
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - B Glass
- AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany
| | - C Gisselbrecht
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| |
Collapse
|
8
|
Brière J, Charbotel B, Gadegbeku B, Smaïli S. Mise au point d’indicateurs de surveillance des accidents de circulation liés au travail en France. ARCH MAL PROF ENVIRO 2015. [DOI: 10.1016/j.admp.2015.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Empereur-Bissonnet P, Fréry N, Provost D, Saura C, Brière J, Buisson C, Berneron B, Garnier R, Castor C, Filleul L, Poujol I, Pilorget C, Gault G, Lapostolle A, Rolland P. Agrégats spatiotemporels de cancers en milieu professionnel : réponse de santé publique par l’Institut de veille sanitaire (InVS) – apport et limite de l’épidémiologie d’investigation. ARCH MAL PROF ENVIRO 2015. [DOI: 10.1016/j.admp.2015.04.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Brière J, Fréry N, Buisson C, Berneron B, Garnier R. Investigation en 2011–2013 d’un cluster de cancers chez un sous-traitant de l’industrie de pointe produisant des pièces en matériaux composites. ARCH MAL PROF ENVIRO 2015. [DOI: 10.1016/j.admp.2014.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
11
|
Chiche J, Pommier S, Beneteau M, Mondragón L, Meynet O, Zunino B, Mouchotte A, Verhoeyen E, Guyot M, Pagès G, Mounier N, Imbert V, Colosetti P, Goncalvès D, Marchetti S, Brière J, Carles M, Thieblemont C, Ricci JE. GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α. Leukemia 2014; 29:1163-76. [PMID: 25394713 DOI: 10.1038/leu.2014.324] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 11/04/2014] [Accepted: 11/10/2014] [Indexed: 12/22/2022]
Abstract
Deregulated expression of glycolytic enzymes contributes not only to the increased energy demands of transformed cells but also has non-glycolytic roles in tumors. However, the contribution of these non-glycolytic functions in tumor progression remains poorly defined. Here, we show that elevated expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), but not of other glycolytic enzymes tested, increased aggressiveness and vascularization of non-Hodgkin's lymphoma. Elevated GAPDH expression was found to promote nuclear factor-κB (NF-κB) activation via binding to tumor necrosis factor receptor-associated factor-2 (TRAF2), enhancing the transcription and the activity of hypoxia-inducing factor-1α (HIF-1α). Consistent with this, inactive mutants of GAPDH failed to bind TRAF2, enhance HIF-1 activity or promote lymphomagenesis. Furthermore, elevated expression of gapdh mRNA in biopsies from diffuse large B-cell non-Hodgkin's lymphoma patients correlated with high levels of hif-1α, vegf-a, nfkbia mRNA and CD31 staining. Collectively, these data indicate that deregulated GAPDH expression promotes NF-κB-dependent induction of HIF-1α and has a key role in lymphoma vascularization and aggressiveness.
Collapse
Affiliation(s)
- J Chiche
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France
| | - S Pommier
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [3] Centre Hospitalier Universitaire de Nice, Département d'Anesthésie Réanimation, Nice, France
| | - M Beneteau
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France
| | - L Mondragón
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France
| | - O Meynet
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France
| | - B Zunino
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France
| | - A Mouchotte
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France
| | - E Verhoeyen
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France
| | - M Guyot
- 1] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [2] Institute for Research on Cancer and Aging, CNRS UMR 7284/U INSERM 1081, Centre A. Lacassagne, Nice, France
| | - G Pagès
- 1] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [2] Institute for Research on Cancer and Aging, CNRS UMR 7284/U INSERM 1081, Centre A. Lacassagne, Nice, France
| | - N Mounier
- Centre Hospitalier Universitaire de Nice, Département d'Onco-Hématologie, Nice, France
| | - V Imbert
- 1] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [2] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'inflammation, cancer et cellules souches cancéreuses', Nice, France
| | - P Colosetti
- 1] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [2] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'mort cellulaire, différenciation, inflammation et cancer', Nice, France
| | - D Goncalvès
- 1] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [2] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'mort cellulaire, différenciation, inflammation et cancer', Nice, France
| | - S Marchetti
- 1] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [2] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'mort cellulaire, différenciation, inflammation et cancer', Nice, France
| | - J Brière
- AP-HP-Hôpital Saint-Louis, Service d'hémato-Oncologie, Université Paris Diderot, Sorbonne Paris Cité, F-75010 Paris, France
| | - M Carles
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [3] Centre Hospitalier Universitaire de Nice, Département d'Anesthésie Réanimation, Nice, France
| | - C Thieblemont
- AP-HP-Hôpital Saint-Louis, Service d'hémato-Oncologie, Université Paris Diderot, Sorbonne Paris Cité, F-75010 Paris, France
| | - J-E Ricci
- 1] Inserm, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), équipe 'contrôle métabolique des morts cellulaires', équipe 3, Nice, France [2] Université de Nice-Sophia-Antipolis, Faculté de Médecine, Nice, France [3] Centre Hospitalier Universitaire de Nice, Département d'Anesthésie Réanimation, Nice, France
| |
Collapse
|
12
|
de Lastours V, LeGoff J, Brière J, Agbalika F, Boulet T, Lévy Y, Simon F, Aboulker JP, Molina JM. Lymphoma and Epstein−Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial. HIV Med 2013; 15:23-9. [DOI: 10.1111/hiv.12077] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/07/2013] [Indexed: 11/29/2022]
Affiliation(s)
- V de Lastours
- Department of Infectious Diseases; Saint-Louis Hospital; Paris France
- University Paris Diderot; Sorbonne Paris Cité; Paris France
| | - J LeGoff
- University Paris Diderot; Sorbonne Paris Cité; Paris France
- Department of Microbiology; Saint-Louis Hospital; Paris France
- INSERM U941; Paris France
| | - J Brière
- University Paris Diderot; Sorbonne Paris Cité; Paris France
- Department of Pathology; Saint-Louis Hospital; Paris France
| | - F Agbalika
- University Paris Diderot; Sorbonne Paris Cité; Paris France
- Department of Microbiology; Saint-Louis Hospital; Paris France
| | - T Boulet
- Institut National Recherche Médicale (INSERM) SC10; Villejuif France
| | - Y Lévy
- INSERM U955; Creteil France
| | - F Simon
- University Paris Diderot; Sorbonne Paris Cité; Paris France
- Department of Microbiology; Saint-Louis Hospital; Paris France
- INSERM U941; Paris France
| | - J-P Aboulker
- Institut National Recherche Médicale (INSERM) SC10; Villejuif France
| | - J-M Molina
- Department of Infectious Diseases; Saint-Louis Hospital; Paris France
- University Paris Diderot; Sorbonne Paris Cité; Paris France
- INSERM U941; Paris France
| |
Collapse
|
13
|
Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol 2012; 24:1032-7. [PMID: 23235801 DOI: 10.1093/annonc/mds600] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients. PATIENTS AND METHODS Untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. RESULTS A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups with a 3-year estimates of 98% and 97%, respectively (P = 0.686). CONCLUSION In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly superior to ACVBP plus consolidation alone.
Collapse
Affiliation(s)
- N Ketterer
- Department of Oncology, University Hospital, Lausanne, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Brière J, Molina TJ, Fabiani B, Petrella T, Bosq J, Gisselbrecht C, Siebert R, Tilly H, Haioun C, Fillet G, Gaulard P. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. Ann Oncol 2012; 23:3143-3151. [PMID: 22700993 DOI: 10.1093/annonc/mds150] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Diffuse large B-cell lymphomas (DLBCLs) arising in specific extranodal sites have peculiar clinicopathologic features. PATIENTS AND METHODS We analyzed a cohort of 187 primary Waldeyer's ring (WR) DLBCLs retrieved from GELA protocols using anthracyclin-based polychemotherapy. RESULTS Most patients (92%) had stage I-II disease. A germinal center B-cell-like (GCB) immunophenotype was observed in 61%, and BCL2 expression in 55%, of WR DLBCLs. BCL2, BCL6, IRF4 and MYC breakpoints were observed in, respectively, 3 of 42 (7%), 9 of 36 (25%), 2 of 26 (8%) and 4 of 40 (10%) contributive cases. A variable follicular pattern was evidenced in 30 of 68 (44%) large biopsy specimens. The 5-year progression-free survival (PFS) and the overall survival (OS) of 153 WR DLBCL patients with survival information were 69.5% and 77.8%, respectively. The GCB immunophenotype correlated with a better OS (P = 0.0015), while BCL2 expression predicted a worse OS (P = 0.037), an effect overcome by the GCB/non-GCB classification. Compared with matched nodal DLBCLs, WR DLBCLs with no age-adjusted international prognostic index factor disclosed a better 5-year PFS rate (77.5% versus 70.7%; P = 0.03). CONCLUSIONS WR DLBCLs display distinct clinicopathologic features compared with conventional DLBCLs, with usual localized-stage disease, common follicular features and a high frequency of GCB immunophenotype contrasting with a low rate of BCL2 rearrangements. In addition, they seem to be associated with a better outcome than their nodal counterpart.
Collapse
Affiliation(s)
- L de Leval
- Department of Laboratories, Institute of Pathology, C.H.U.V. Lausanne, Lausanne, Switzerland.
| | - C Bonnet
- Department of Clinical Hematology, C.H.U. of Liège, Liège, Belgium
| | - C Copie-Bergman
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil; Department of Medicine, Paris-Est University, Créteil, France
| | - L Seidel
- Department of Biostatistics, Liège University, Liège, Belgium
| | - M Baia
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil
| | - J Brière
- INSERM U728, Saint-Louis Hospital, Paris; Department of Pathology, Saint Louis Hospital, AP-HP, Paris
| | - T J Molina
- Department of Pathology, Hôtel-Dieu Hospital, AP-HP, Paris Descartes University, Paris
| | - B Fabiani
- Department of Pathology, Saint-Antoine Hospital, Paris
| | | | - J Bosq
- Department of Biopathology, Morpological Unit, Gustave Roussy Institute, Villejuif, France
| | | | - R Siebert
- Institute of Human Genetics, Christian-Albrechts-University, Kiel; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - H Tilly
- Department of Hematology, UMR918, Henri Becquerel Center, Rouen University, Rouen, France
| | - C Haioun
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil; Department of Medicine, Paris-Est University, Créteil, France
| | - G Fillet
- Department of Clinical Hematology, C.H.U. of Liège, Liège, Belgium
| | - P Gaulard
- Lymphoid Malignancies Unit, Henri-Mondor Hospital, AP-HP, Créteil; INSERM U955, Henri-Mondor Hospital, Créteil; Department of Medicine, Paris-Est University, Créteil, France
| |
Collapse
|
15
|
Amegbor K, Harimenshi JM, Bin Asker A, Brière J, de Roquancourt A, Meignin V, Vérine J, Roche B, Benet C, Grossin M, Loiseaux F, Battistella M, Osio A, Rivet J, Janin A, Ameisen D, Bertheau P. La classification histopathologique simplifiée des tumeurs présentée à l’aide d’un outil pédagogique collaboratif en ligne en mode zoom. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
16
|
Chevalier A, Brière J, Feurprier M, Paboeuf F, Imbernon E. Mise en évidence des secteurs d’activité économique à haut risque d’accident du travail : utilisation d’un outil de surveillance construit à partir des données de réparation des régimes de sécurité sociale. ARCH MAL PROF ENVIRO 2012. [DOI: 10.1016/j.admp.2012.09.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
17
|
de Kerviler E, Benet C, Brière J, de Bazelaire C. Image-guided needle biopsy for diagnosis and molecular biology in lymphomas. Best Pract Res Clin Haematol 2012; 25:29-39. [DOI: 10.1016/j.beha.2012.01.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
18
|
Michenet P, Bouchy C, Bonneau C, Kerdraon R, Heitzmann A, Blechet C, Brière J. Double lecture systématique des lymphomes : évaluation d’une année d’activité d’un centre hospitalier. Ann Pathol 2011. [DOI: 10.1016/j.annpat.2011.09.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
19
|
Khoudri I, Frémont G, Flageul B, Brière J, Dubertret L, Viguier M. [Bilateral inguinal lymphadenopathy and erythema nodosum: an uncommon presentation of cat scratch disease]. Rev Med Interne 2010; 32:e34-6. [PMID: 20646798 DOI: 10.1016/j.revmed.2009.11.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Revised: 09/14/2009] [Accepted: 11/25/2009] [Indexed: 10/19/2022]
Abstract
Cat scratch disease is usually revealed by a proximal lymphadenopathy related to the inoculation site. We report a 22-year-old female who presented with erythema nodosum and bilateral inguinal lymphadenopathy. Serologic test and lymph node PCR detection for Bartonella henselae were negative. Nevertheless, the patient received doxycycline and clinical manifestations rapidly resolved. A follow-up detection of IgM and IgG against Bartonella henselae performed 1 month later was positive. This case report illustrates an original presentation of cat scratch disease and reminds us the lack of sensitivity of laboratory investigations.
Collapse
Affiliation(s)
- I Khoudri
- Service de dermatologie, université Paris-VII Denis-Diderot, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1 avenue Claude-Vellefaux, Paris cedex 10, France
| | | | | | | | | | | |
Collapse
|
20
|
Feuillet S, Meignin V, Brière J, Brice P, Rocha V, Socié G, Tazi A, Bergeron A. Endobronchial Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Transplantation. Clin Med Case Rep 2009; 2:11-5. [PMID: 24179366 PMCID: PMC3785368 DOI: 10.4137/ccrep.s2084] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
The Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disorders (PTLD) are increasingly recognized as a fatal complication of hematological stem cell transplantation (HSCT). Thoracic involvement, that may be isolated or part of a disseminated disease, usually encompasses pulmonary nodules or masses and mediastinal lymph node enlargement. The current case study presents 2 patients who underwent HSCT, one allogenic and the other autologous, who developed an exceptional endobronchial EBV related PTLD. The first patient had a fleshy white endobronchial mass resulting in a right upper lobe atelectasis and the second had an extensive necrotising mucosa from trachea to both basal bronchi without any significant change of lung parenchyma on the CT scan. In both cases, the diagnosis was made by bronchial biopsies. Physicians should be aware of an endobronchial pattern of EBV associated PTLD after HSCT to permit quick diagnosis and therapeutic intervention.
Collapse
Affiliation(s)
- S Feuillet
- Université Denis Diderot-Paris 7, Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Biasoli I, Franchi-Rezgui P, Sibon D, Brière J, de Kerviler E, Thieblemont C, Levy V, Gisselbrecht C, Brice P. Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. Ann Oncol 2008; 19:1915-20. [DOI: 10.1093/annonc/mdn391] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Diebold J, Le Tourneau A, Marmey B, Prevot S, Müller-Hermelink HK, Sevestre H, Molina T, Billotet C, Gaulard P, Knopf JF, Bendjaballah S, Mangnan-Marai A, Brière J, Fabiani B, Audouin J. Is sclerosing angiomatoid nodular transformation (SANT) of the splenic red pulp identical to inflammatory pseudotumour? Report of 16 cases. Histopathology 2008; 53:299-310. [DOI: 10.1111/j.1365-2559.2008.03101.x] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22:1917-24. [PMID: 18615101 DOI: 10.1038/leu.2008.188] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarrays, we analyzed the lymphoma transcriptional profile of 30 patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and 23 patients treated with rituximab (R)-CHOP in the Groupe d'Etude des Lymphomes de l'Adulte clinical centers. We used this data set to select transcripts showing an association with progression-free survival in all patients or showing a differential effect in the two treatment groups. We performed real-time quantitative reverse transcription-PCR in the 23 R-CHOP samples of the screening set and an additional 44 R-CHOP samples set to evaluate the prognostic significance of these transcripts. In these 67 patients, the level of expression of 16 genes and the cell-of-origin classification were significantly associated with overall survival, independently of the International Prognostic Index. A multivariate model comprising four genes of the cell-of-origin signature (LMO2, MME, LPP and FOXP1) and two genes related to immune response, identified for their differential effects in R-CHOP patients (APOBEC3G and RAB33A), demonstrated a high predictive efficiency in this set of patients, suggesting that both features affect outcome in DLBCL patients receiving immunochemotherapy.
Collapse
Affiliation(s)
- J-P Jais
- Service de Biostatistique, AP-HP, hôpital Necker, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Gallien S, Lagrange-Xelot M, Crabol Y, Brière J, Galicier L, Molina JM. [Systemic lupus erythematosus and Kikuchi-Fujimoto disease mimicking tuberculosis]. Med Mal Infect 2008; 38:392-5. [PMID: 18565709 DOI: 10.1016/j.medmal.2008.03.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2007] [Revised: 08/06/2007] [Accepted: 03/05/2008] [Indexed: 11/20/2022]
Abstract
Kikuchi-Fujimoto's disease (KFD) or histiocytic narcotising lymphadenitis is a febrile benign lymphadenopathy of unknown etiology, involving more frequently cervical lymph nodes and diagnosed on biopsy of an affected node. It is sometimes associated with auto-immune diseases such as systemic lupus erythematosus (SLE). However less frequent symptoms including involvement of extracervical nodes, hepatosplenomegaly and systemic symptoms (weight loss, night sweats) are possible and suggest an infectious disease. We report the case of a Senegalese patient with positive Ag HBs who developed SLE and KFD mimicking tuberculosis. Atypical pseudo-infectious appearance of an inflammatory systemic disease is a rare occurrence and the diagnosis can be difficult.
Collapse
Affiliation(s)
- S Gallien
- Service de maladies infectieuses et tropicales, hôpital Saint-Louis, 1, avenue Claude-de-Vellefaux, 75010 Paris, France.
| | | | | | | | | | | |
Collapse
|
25
|
Morel P, Gaulard P, Gisselbrecht C, Ferme C, Salles G, Tilly H, Brière J, Copin M, Lederlin P, Hermine O, Theate I, Haioun C, Mounier N. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Ann Oncol 2008; 19:560-5. [DOI: 10.1093/annonc/mdm520] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Svrcek M, Meignin V, Brière J, Quillard J, Mariette X, Audouin J, Janin A. Multiple myeloma with loss of CD138 expression in two rare metastatic localizations, peritoneum and skin. Histopathology 2007; 50:952-4. [PMID: 17543089 DOI: 10.1111/j.1365-2559.2007.02694.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
De leval L, Rickman D, Thielen C, De Reynies A, Huang YE, Theate Y, Molina T, Brière J, Gisselbrecht C, Berger F, Xerri L, Gaulard P. Le profil d’expression génique des lymphomes T angio-immunoblastiques diffè de celui des lymphomes T périphériques sans spécificité et présente des analogies avec celui des cellules T Helper folliculaires(TFH). Ann Pathol 2006. [DOI: 10.1016/s0242-6498(06)70781-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004; 15:1790-7. [PMID: 15550584 DOI: 10.1093/annonc/mdh471] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Data are still conflicting on the indication of front-line autologous stem-cell transplantation (ASCT) as consolidation for aggressive lymphoma. To assess the therapeutic effect of ASCT among different aggressive lymphoma subtypes, we conducted a matched-control analysis by pooling the data from two Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. PATIENTS AND METHODS Between October 1987 and September 1998, 330 patients received ASCT after achieving complete remission with the ACBVP induction regimen. The histological slides showed: B aggressive non-Hodgkin's lymphoma (B-NHL) in 249 patients (75%), T-NHL in 52 patients (15%) (including 23 T anaplastic) and non-classified NHL in 29 patients. The age-adjusted International Prognostic Index (aaIPI) was 2 or 3 in 66%. Patients were matched with controls from the same GELA database but treated with chemotherapy only. RESULTS ASCT did not benefit non-anaplastic T-NHL patients [5-year overall survival (OS) 44% (chemotherapy) versus 49% (ASCT), P=0.87; disease-free survival (DFS) 38% versus 45%, P=0.89] in comparison with B-NHL [5-year OS 77% (chemotherapy) versus 79% (ASCT), P=0.64; DFS 67% versus 72%, P=0.13]. However, for B-NHL patients with aaIPI score 2 or 3, the benefit of ASCT was significant. CONCLUSIONS This cohort study confirms the high efficacy of front-line ASCT in responding aggressive B-NHL patients with adverse prognostic factors.
Collapse
Affiliation(s)
- N Mounier
- Hôpital Saint Louis, AP-HP, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Camilleri-Broët S, Mounier N, Delmer A, Brière J, Casasnovas O, Cassard L, Gaulard P, Christian B, Coiffier B, Sautès-Fridman C. FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). Leukemia 2004; 18:2038-40. [PMID: 15470484 DOI: 10.1038/sj.leu.2403536] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
30
|
Saadoun D, Cazals-Hatem D, Denninger MH, Boudaoud L, Pham BN, Mallet V, Condat B, Brière J, Valla D. Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome. Gut 2004; 53:1516-9. [PMID: 15361506 PMCID: PMC1774222 DOI: 10.1136/gut.2003.037135] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Isolated sinusoidal dilatation is an uncommon hepatic lesion and the cause is largely unknown. OBJECTIVE To investigate whether prothrombotic disorders or perisinusoidal cell changes could be involved in pure idiopathic hepatic sinusoidal dilatation (HSD). METHODS Evaluation for associated conditions, prothrombotic disorders, and studies of hepatic perisinusoidal cell activation in consecutive patients, seen between 1993 and 2002, with isolated sinusoidal dilatation unrelated to outflow block, sinusoidal infiltration, or hepatic granulomas. RESULTS Among 11 patients, associated conditions were prothrombotic disorders (n = 5) and oral contraceptive use (n = 3). Prothrombotic disorders were polycythemia vera (n = 1) and anticardiolipin antibodies combined with lupus anticoagulant (n = 4). No genetic thrombophilia factor was found. Of four patients with lupus anticoagulant, three had antinuclear factors and high serum levels of anticardiolipin antibodies at repeated testing. There was no evidence of intrahepatic or extrahepatic thrombosis in any of the patients. Sinusoidal dilatation was marked in six of 11 patients (54%), including two patients with antiphospholipid antibodies. Activated perisinusoidal cells were only found around markedly dilated sinusoids. CONCLUSION Idiopathic pure HSD is frequently associated with the immunological features of the antiphospholipid syndrome. Therefore, finding pure HSD in a liver biopsy specimen should prompt the search for antiphospholipid antibodies.
Collapse
Affiliation(s)
- D Saadoun
- Service d'Hépatologie, Hôpital Beaujon, 92118 Clichy, France
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Simon J, Lortholary O, Caillat-Vigneron N, Raphaël M, Martin A, Brière J, Barète S, Hermine O, Casassus P. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. ACTA ACUST UNITED AC 2004; 52:294-9. [PMID: 15217717 DOI: 10.1016/j.patbio.2004.04.012] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2004] [Accepted: 04/13/2004] [Indexed: 01/03/2023]
Abstract
Systemic mastocytosis (SM) are defined by an abnormal growth and accumulation of mast cells in bone marrow and/or other extracutaneous organs. There is currently no cure for this disease. Because of similarities and/or association of mastocytosis with myeloproliferative disorders, interferon alpha has been tested but with contradictory reported results. A first prospective multicenter phase II trial was then started in France. From 1994 to 1997, 20 adult patients with confirmed bone marrow involvement received interferon alpha-2b for at least 6 months, (from 1 million U per day up to 5 million U/m(2)/day). Thirteen patients who presented systemic and/or specific cutaneous manifestations, demonstrated objective responses: seven (35%) were partial, six (30%) minor but no complete response could be observed at the time of analysis. The bone marrow remained unchanged in 12/13. Thus, interferon should be offered to patients with severe systemic manifestations, who have not responded to symptomatic therapies, even in case of non-aggressive mastocytosis, with or without corticosteroids the first weeks. Long-term therapy should be offered to patients with initial positive response. To control more aggressive SM or mastocytosis associated with clonal hematologic non-mast cell lineage or leukaemia mast cell, other chemotherapeutic regimens should be proposed like Cladribine (2-chlorodeoxyadenosine, 2-CDA) or polychemotherapies including interferon as it is being tested in France in a new multicentric protocol, coordinated by the association AFIRMM, with interferon and oral cytarabine.
Collapse
Affiliation(s)
- J Simon
- Service de médecine Interne-néphrologie, Centre hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, 10, rue Champ Gaillard, 78300 Poissy, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Morel P, Mounier N, Brière J, Ferme C, Coiffier B, Tilly H, Gaulard P, Lederlin P, Reyes F, Gisselbrecht C. Autologous stem cell transplantation (ASCT) as consolidation therapy for patients with low-intermediate (LI) risk diffuse large B-cell lymphoma (DLBCL) and overexpression of bcl2 protein. Results of the first interim analysis of the GELA trial LNH98-B2. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Morel
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - N. Mounier
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - J. Brière
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - C. Ferme
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - B. Coiffier
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - H. Tilly
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - P. Gaulard
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - P. Lederlin
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - F. Reyes
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| | - C. Gisselbrecht
- Hôpital Schaffner, Lens, France; Hôpital Saint Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Becquerel, Rouen, France; Hôpital Henri Mondor, Creteil, France; Centre Hospitalier Universitaire, Nancy, France
| |
Collapse
|
33
|
Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F. Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2004; 22:2826-34. [PMID: 15254050 DOI: 10.1200/jco.2004.12.032] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Improved survival has been observed in aggressive non-Hodgkin's lymphoma (NHL) patients with adverse prognostic factors when autotransplantation (ASCT) was performed after complete remission. However, there is no agreement on the prognostic factors for patients treated with ASCT. We aimed to estimate the prognostic effect of clinical and biologic variables on relapse and survival rates by pooling the data from two trials. Patients and Methods Of the patients treated in the LNH87 and LNH93 trials, 330 under age 60 years achieved complete remission after high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone, and received consolidative ASCT; 16% of patients had T-cell NHL. The International Prognostic Index (IPI) score was 0 for 11%, 1 for 23%, 2 for 51%, and 3 for 15%. Univariate and Cox multivariate survival analyses were retrospectively performed on this population. Results Overall survival was 75 ± 5% at 5 years and disease-free survival (DFS) 67 ± 5%. For T-cell NHL, these scores were 54% and 44%, respectively. The IPI score had no prognostic value and only the following parameters adversely affected overall survival and DFS (P < .05): marrow involvement; more than one extranodal site; histology (nonanaplastic T-cell v others); and type of anthracycline (mitoxantrone v doxorubicin, for DFS only). Conclusion These results suggest that ASCT can prevent relapse in patients with adverse IPI factors. However, patients presenting with a nonanaplastic T-cell phenotype, more than one extranodal site, or marrow involvement still have a higher risk of relapse. These factors should be taken into account when designing post-ASCT maintenance studies.
Collapse
Affiliation(s)
- N Mounier
- Service d'Onco-Hématologie, INSERM ERM0220, Hôpital Saint Louis, AP-MP, 1 Avenue Claude Vellefaux, 75010 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Le Gouill S, Lepretre S, Brière J, Morel P, Bouabdallah R, Raffoux E, Sebban C, Lepage E, Brice P. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 2003; 17:2220-4. [PMID: 14576732 DOI: 10.1038/sj.leu.2403095] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Since 1987, the GELA has initiated multicenter prospective trials for aggressive non-Hodgkin's lymphomas (NHL). Lymphoblastic lymphomas (LBL) were included in those studies until 1997, and 92 LBL patients under 61 years were identified after histological review. The protocols prescribed high-dose anthracycline regimens, four cycles given every 15 days as induction and lasted for </=6 months. A total of 23 patients underwent high-dose therapy consolidation followed by autologous stem-cell transplantation and 69 received standard chemotherapy regimens. Clinical characteristics showed a male predominance (66%) with a median age of 31 years, bone marrow (BM) involvement (22%), mediastinal involvement (66%) and elevated LDH (62%). At the end of treatment, it was seen that 71% of the patients achieved complete remission; four (4%) patients died during induction; 43 patients relapsed at a median time of 10 months. With a median follow-up of 34 months, the 5-year overall survival (OS) and event-free survival (EFS) rates were 32 and 22%, respectively. The only favorable factor significantly associated with survival was young age. These results are poorer than those obtained in other aggressive lymphomas treated with the same regimens and suggest that adult LBL patients should be treated with acute lymphoblastic leukemia protocols.
Collapse
|
35
|
Theate I, Michaux L, Dardenne S, Guiot Y, Brière J, Emile FJ, Fabiani B, Detry R, Gaulard P. Epstein-Barr virus-associated lymphoproliferative disease occurring in a patient with sarcoidosis treated by methotrexate and methylprednisolone. Eur J Haematol 2002; 69:248-53. [PMID: 12431245 DOI: 10.1034/j.1600-0609.2002.02748.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We describe the case of a 51-yr-old man with systemic sarcoidosis, complicated by the occurrence of a lymphoproliferative disease following a 36-month (duration) immunosuppressive treatment with methotrexate (MTX) and methylprednisolone. Four years after the onset of sarcoidosis, the patient presented a large necrotizing anal fistula. Pathological examination of this lesion showed a diffuse polymorphic infiltrate containing large Epstein-Barr virus (EBV)-positive lymphoid cells associated with areas of necrosis, all features similar to classical B-cell lymphoproliferative disorders occurring in immunosuppressed solid-organ recipients. MTX has been recently implicated in the development of lymphoproliferative disease in connective tissue diseases. This case supports the hypothesis that immunosuppression therapy may contribute to an increased risk for the development of EBV-associated lymphoproliferative disorders in patients suffering from sarcoidosis.
Collapse
Affiliation(s)
- I Theate
- Department of Pathology, Cliniques Universitaires Saint Luc, Université catholique de Louvain, Avenue Hippocrate 10, B-1200 Brussels, Belgium.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Morel P, Souleau B, Morschhauser F, Duhamel A, Dombret H, Tilly H, Reyes F, Brière J, Coiffier B, Celigny PS, Lepage E, Brousse N. Assessing the Cox model assumption as a statistical tool for classifying lymphomas. Hematol J 2002; 2:341-51. [PMID: 11920270 DOI: 10.1038/sj.thj.6200125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2000] [Accepted: 11/24/2000] [Indexed: 11/09/2022]
Abstract
INTRODUCTION The Cox model is widely used in medical research for comparing survival. Lymphomas might exhibit important differences in long-term cure rate despite a similar survival. METHODS Using log-rank test, we compared event-free survival (EFS), and the survival of 64 patients with mantle cell lymphoma (MCL), 525 patients with follicular lymphoma, and 1136 patients with diffuse centroblastic lymphoma (CB). RESULTS Although EFS and survival of MCL were significantly shorter than those of follicular lymphoma, checking the validity of the proportional hazards assumption shows that the distribution of rates of events and deaths over time did not differ in MCL and follicular lymphoma. In contrast, the ratios of hazards (events and deaths rates) did not remain constant over time in MCL and CB, because of a decrease in late events and deaths rates in the latter histological type. CONCLUSION Checking the validity of the Cox model hypothesis might be a useful tool for assessing long-term cure rate in seldom lymphoma subtypes. Despite a short overall survival, MCL should not be considered to be an aggressive lymphoma, in which available chemotherapy may cure a subset of patients.
Collapse
Affiliation(s)
- P Morel
- Service d' Hématologie Clinique, Centre Hospitalier Schaffner, 62300 Lens, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Maloisel F, Guerci A, Guyotat D, Ifrah N, Michallet M, Reiffers J, Tertain G, Blanc M, Bauduer F, Brière J, Abgrall JF, Pegourie-Bandelier B, Solary E, Cambier N, Coso D, Vilque JP, Delain M, Harousseau JL, Rousselot P, Belhadj K, Morice P, Attal J, Chabin M, Chastang C, Guilhot J, Guilhot F. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia 2002; 16:573-80. [PMID: 11960335 DOI: 10.1038/sj.leu.2402433] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2001] [Accepted: 12/13/2001] [Indexed: 11/09/2022]
Abstract
Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to systemic deamination after oral administration. Following initial studies indicating significant anti-tumour activity of YNK01 a phase II trial was initiated in order to assess the tolerability and efficacy of a combination of this agent with interferon alpha-2b (IFN-alpha2b) in recently diagnosed chronic phase CML patients (n = 98). The treatment was subdivided into cycles consisting of 4 weeks of continuous administration of IFN-alpha-2b (3 MU/m(2)/day 1st week and then 5 MU/m(2)/day) and 14 days of oral YNK01 (600 mg/day 1st cycle). At the end of each cycle the dose of YNK01 was adjusted according to the blood count observed during the previous 4 weeks. The median time from diagnosis to inclusion in the trial was 2 months (range 6 days to 7.5 months). At 12 weeks, 62 patients (63%; 95% CI, 54-73) achieved a complete hematological response. At 24 weeks, of 98 patients, two achieved a complete cytogenetic response, 14 a partial response (16% major cytogenetic response rate; 95% CI, 9-24) and 34 a minor response; 19 patients were not evaluable for cytogenetic response. During the trial, 20 patients progressed to accelerated (6) or blastic phases (14). The median time to progression was 15 months (range 2-38 months). At 3 years the overall survival was 79% (95% CI, 70-88). Although the complete hematological response rate compared favorably with the 40% response rate previously obtained with the subcutaneous formulation of Ara-c, the cytogenetic response rate was less than expected. Most of the patients experienced side-effects and all permanently stopped YNK01. Although the combination seems attractive the initial dose of 600 mg per day is probably too high and should be reconsidered in further trials.
Collapse
MESH Headings
- Administration, Oral
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Arabinonucleotides/administration & dosage
- Cytidine Monophosphate/administration & dosage
- Cytidine Monophosphate/analogs & derivatives
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Interferon alpha-2
- Interferon-alpha/administration & dosage
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukemia, Myeloid, Chronic-Phase/drug therapy
- Leukemia, Myeloid, Chronic-Phase/mortality
- Leukemia, Myeloid, Chronic-Phase/pathology
- Male
- Middle Aged
- Prognosis
- Recombinant Proteins
- Risk Factors
- Survival Rate
Collapse
Affiliation(s)
- F Maloisel
- Division of Hematology, University Hospital of Strasbourg, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
|
39
|
Roussel M, Meignin V, Brière J, Daniel MT, Brouet JC, Janin A. [A macroglobulinemia with an unusual bone marrow aspect]. Ann Pathol 2001; 21:277-8. [PMID: 11468571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- M Roussel
- Service d'Anatomie Pathologique, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, Paris Cedex, France
| | | | | | | | | | | |
Collapse
|
40
|
Li Y, Brière J, Zhai M. [In vitro autonomous growth of megakaryocytic progenitors and the role of thrombopoietin (Tpo) in essential thrombocythemia]. Zhonghua Xue Ye Xue Za Zhi 2001; 22:300-2. [PMID: 11877088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
OBJECTIVE To investigate in vitro autonomous growth of megakaryocytic progenitors and the role of Tpo in essential thrombocythemia (ET). METHODS Purified bone marrow and peripheral blood CD(34)(+) cells and nonadherent mononuclear cells (NMNC) from patients with ET were cultured to assay the spontaneous megakaryocyte colony formation. The autocrine and paracrine of Tpo in the spontaneous growth cells in liquid culture were examined by RT-PCR. The effect of Tpo on megakaryocytic progenitors was observed by addition of Tpo into CD(34)(+) cell culture. RESULTS There was no spontaneous CFU-MK growth in purified CD(34)(+) cell culture and spontaneous megakaryocyte colonies disappeared at NMNC cell concentrations of 10(4)/ml and 10(3)/ml. There was no Tpo expression in the spontaneous growth cells in liquid culture. Addition of Tpo to the culture of purified CD(34)(+) cells resulted in the formation of megakaryocyte colonies. CONCLUSION In vitro spontaneous CFU-MK formation in ET patients is not from autonomous growth of megakaryocyte progenitors. There is no autocrine or paracrine Tpo secretion. Megakaryocyte progenitors may be hypersensitive to Tpo or other MK-CSF.
Collapse
Affiliation(s)
- Y Li
- Department of Hematology, The First Clinical College, China Medical University, Shenyang 110001, China
| | | | | |
Collapse
|
41
|
Camilleri-Broët S, Audouin J, Fermé C, Brière J, Pulford K, Gaulard P, Diviné M, Macintyre E, Delsol G, Berger F. ALK is not expressed in Hodgkin disease. Blood 2001; 97:1901-2. [PMID: 11263444 DOI: 10.1182/blood.v97.6.1901] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Cazals-Hatem D, André M, Mounier N, Copin MC, Divine M, Berger F, Bosly A, Kerneis Y, Brière J, Quesnel B, Diebold J, Gaulard P. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol 2001; 25:297-306. [PMID: 11224599 DOI: 10.1097/00000478-200103000-00003] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Between 1987 and 1993, 77 of 2855 lymphomas included in the LNH87 protocol of the GELA as non-Hodgkin lymphoma (NHL) and reviewed by a panel of pathologists had a diagnosis changed to Hodgkin lymphoma (HL). Some of these lymphomas had been initially interpreted as anaplastic large-cell lymphoma Hodgkin-like (ALCL-HL subtype). The purpose of this study was to analyze the histologic pitfalls initially encountered, to define more clearly the diagnostic criteria of lymphomas placed in the gray zone around HL, and to follow the survival of these 77 patients affected with HL and initially treated with NHL regimens. The 77 cases of HL were reviewed by three hematopathologists and immunostained with a large panel of antibodies, including CD30, CD15, CD3, CD20, CD45, CD43, LMP-1, EMA, BNH-9, TiA1, and ALK1. Each case was classified according to the Lukes-Rye system and the British National Lymphoma Investigation (BNLI) grading. The initial clinical presentation of patients was analyzed, and the overall and event-free survival rates of the 77 patients were estimated. Among the 77 HLs, 46 were misinterpreted as NHL by primary individual pathologists (12 as ALCL, 8 as ALCL-HL, 12 as peripheral T-cell lymphoma (PTCL), 6 as B-cell lymphoma, and 8 as unclassifiable NHL). The other 31 cases had been first considered by the panel as consistent with ALCL-HL (n = 18) or with PTCL (n = 13) and were changed later in view of an immunophenotype concordant with HL. Fifty-five percent of the patients completed the full NHL treatment. The 5-year event-free and overall survival rates were 54% and 77%, respectively. The current results indicate that lymphomas initially called ALCL-HL should not be regarded as a variant of ALCL, but as HL. The clinical consequences of misdiagnoses seem to be a lower event-free survival rate compared with that of classical HL, probably because of more relapses of initially inappropriately treated HL.
Collapse
Affiliation(s)
- D Cazals-Hatem
- Service d'Anatomie Pathologique, Hôpital Beaujon, AP-HP, Clichy, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Brière J. Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders. Pathol Biol (Paris) 2001; 49:138-9. [PMID: 11317958 DOI: 10.1016/s0369-8114(00)00018-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Abstract
In its anatomy and physiology the pig is comparable with humans and its organs can be considered for xenotransplantation. We have studied the lymphatic drainage of the heart and lungs in 15 pigs. A coloured mass was injected into the myocardium and/or beneath the visceral pleura. The first nodes coloured were directly injected again. No lymph node was observed inside the heart and lungs. The first lymph nodes coloured were the peritracheobronchial nodes. There was no node in front of the thoracic trachea (Barety's compartment in man). Left suprabronchial nodes were connected with the thoracic duct in the mediastinum. The lymphatics of the heart and lungs in the pig are similar to those of human. Phylogenesis explains "skipping" metastases and the significance of N1 disease in lung cancer, as well as chylothorax occurring after heart and lung surgery.
Collapse
Affiliation(s)
- M Riquet
- Service de Chirurgie Thoracique, Hôpital Laënnec, Paris, France
| | | | | | | | | | | |
Collapse
|
45
|
Abstract
BACKGROUND The role of factor V Leiden as a cause of Budd-Chiari syndrome has only recently been described. AIMS To assess the specific features of factor V Leiden related Budd-Chiari syndrome. PATIENTS Sixty three consecutive patients with hepatic vein or terminal inferior vena cava thrombosis. METHODS Standardised chart review. RESULTS Factor V Leiden was found in 20 patients (31% (95% CI 20-43)). In the subgroup of patients with, compared with the subgroup without, factor V Leiden, a combination of prothrombotic states was more common (70% (95% CI 50-90) v 14% (95% CI 3-24)); inferior vena cava thrombosis was more frequent (40% (95% CI 19-61) v 7% (95% CI 0-14)); and distribution of initial alanine aminotransferase values was bimodal (almost normal or extremely increased) versus unimodal (p=0.003). Factor V Leiden accounted for four of five cases of massive ischaemic necrosis (transaminases >50-fold the upper limit of normal values) (p=0.014), and also for all three cases developing during pregnancy. Patients with and without factor V Leiden did not differ with regard to mortality, portosytemic shunting, or listing for liver transplantation. Hepatocellular carcinoma developed in two patients; both had factor V Leiden and indolent obstruction of the inferior vena cava. CONCLUSIONS In patients with Budd-Chiari syndrome, factor V Leiden (a) is common; (b) precipitates thrombosis mostly when combined with another risk factor; (c) is associated with one of two contrasting clinical pictures: indolent thrombosis-particularly of the inferior vena cava-or massive ischaemic necrosis; and (d) is a major cofactor of Budd-Chiari syndrome developing during pregnancy.
Collapse
Affiliation(s)
- P Deltenre
- Service d'Hépatologie, Hôpital Beaujon, Clichy, France
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Lacoste V, Judde JG, Brière J, Tulliez M, Garin B, Kassa-Kelembho E, Morvan J, Couppié P, Clyti E, Forteza Vila J, Rio B, Delmer A, Mauclère P, Gessain A. Molecular epidemiology of human herpesvirus 8 in africa: both B and A5 K1 genotypes, as well as the M and P genotypes of K14.1/K15 loci, are frequent and widespread. Virology 2000; 278:60-74. [PMID: 11112482 DOI: 10.1006/viro.2000.0629] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We have studied 52 new HHV8 strains by sequencing the complete hypervariable K1 gene and genotyping the K14.1/K15 loci located at both sides, respectively, of the viral genome. The samples originated from 49 patients with Kaposi's sarcoma (KS; 32 patients), multicentric Castleman's disease (MCD; 12 patients), or primary effusion lymphoma (PEL; 5 patients). Among these patients, 32 were of African origin (West and Central African countries and Creoles from French Guiana) and the 17 others were mostly French homosexuals. Comprehensive phylogenetic studies allowed the identification of distinct groups within the three already known main subtypes. Interestingly, two new sequences that did not cluster within a known subtype or group could be considered as prototypes of early/ancient variants of the C subtype and A/C set, respectively. Among the 32 African strains, the majority were either of the B subtype (13 cases) or of the A5 group (11 cases), indicating that this latter genotype is frequent and widespread in Africa. In contrast, a subtype C strain infected most of the 17 other patients. PCR-based genotyping of the K14.1/K15 loci revealed an overall predominance of P subtype, except in the A5 and B K1 groups, in which the P and M alleles were equally represented. The implications of these data on the evolution and spread of HHV8 among human African populations are discussed.
Collapse
Affiliation(s)
- V Lacoste
- Unité d'Oncologie Virale, Département du SIDA et des Rétrovirus, Institut Pasteur, 25-28 rue du Dr. Roux, Paris Cedex 15, 75724, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Brière J, Gaulard P, Reyes F. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18:3025-30. [PMID: 10944137 DOI: 10.1200/jco.2000.18.16.3025] [Citation(s) in RCA: 327] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To present the final analysis, with a median follow-up of 8 years, of the LNH87-2 randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine) with high-dose therapy (HDT) using cyclophosphamide, carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation in patients with aggressive non-Hodgkin's lymphoma in first complete remission after induction, focusing on high/intermediate- and high-risk patients identified by the age-adjusted international prognostic index. PATIENTS AND METHODS Among the 916 eligible patients, 451 presented with two (n = 318) or three (n = 133) risk factors. After reaching complete remission to induction therapy, 236 of these higher risk patients were assessable for the consolidation phase, with 125 patients in the HDT arm and 111 in the sequential chemotherapy arm. RESULTS Among these 451 higher risk patients, 277 (61%) achieved complete remission after induction treatment. In the population of 236 randomized patients, HDT was superior to sequential chemotherapy, with 8-year disease-free survival rates of 55% (95% confidence interval [CI], 46% to 64%) and 39% (95% CI, 30% to 48%), respectively (P =.02; relative risk, 1.56). The 8-year survival rate was significantly superior in the HDT arm (64%; 95% CI, 55% to 73%) compared with the sequential chemotherapy arm (49%; 95% CI, 39% to 59%) (P =.04; relative risk, 1.51). CONCLUSION On the basis of the final analysis of this prospectively treated series of patients, retrospectively analyzed on the basis of the International Prognostic Index, we hypothesize that HDT benefits patients at higher risk who achieve complete remission after induction treatment.
Collapse
Affiliation(s)
- C Haioun
- Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Patey-Mariaud De Serre N, Cellier C, Jabri B, Delabesse E, Verkarre V, Roche B, Lavergne A, Brière J, Mauvieux L, Leborgne M, Barbier JP, Modigliani R, Matuchansky C, MacIntyre E, Cerf-Bensussan N, Brousse N. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology 2000; 37:70-7. [PMID: 10931221 DOI: 10.1046/j.1365-2559.2000.00926.x] [Citation(s) in RCA: 121] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
AIMS We recently showed that refractory sprue is distinct from coeliac disease, the former being characterized by abnormal intraepithelial T-lymphocytes expressing a cytoplasmic CD3 chain (CD3c), lacking CD3 and CD8 surface expression, and showing TCRgamma gene rearrangements. To take advantage of the abnormal phenotype of CD3c + CD8 - intraepithelial lymphocytes (IEL) in refractory sprue we developed a simple method to distinguish coeliac disease from refractory sprue. METHODS AND RESULTS Comparative immunohistochemical studies using anti-CD3 and anti-CD8 antibodies were applied on paraffin-embedded and frozen biopsy specimens in refractory sprue (n = 6), coeliac disease (n = 10), healthy controls (n = 5) and suspected refractory sprue (n = 6). Comparable results were obtained on fixed and frozen biopsy specimens. In four of the six patients with suspected refractory sprue, abnormal CD3c + CD8 - IEL and TCRgamma gene rearrangements were found, as in refractory sprue; the remaining two patients had normal (CD3 + CD8 +) IEL and no TCRgamma gene rearrangements. Both patients had coeliac disease, as one failed to comply with a gluten-free diet, while the other was a slow responder. CONCLUSION This simplified immunostaining method using anti-CD3 and anti-CD8 antibodies on paraffin sections can distinguish active coeliac disease from refractory sprue and should prove useful in clinical practice.
Collapse
Affiliation(s)
- N Patey-Mariaud De Serre
- Department of Pathology and Université René Descartes-Paris V (EA 219), INSERM E 9925, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, Brière J, Reyes F. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11:685-90. [PMID: 10942056 DOI: 10.1023/a:1008394827806] [Citation(s) in RCA: 151] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Incidence of central nervous system (CNS) recurrence in patients with aggressive non-Hodgkin's lymphoma who did not receive meningeal prophylaxis is about 5%. Controversy remains regarding risk factors associated with such an event preventing a rational approach of prophylactic strategies. PATIENTS AND METHODS We analyzed a cohort of 974 patients with aggressive lymphoma in complete remission (CR). All the patients received a CNS prophylaxis consisting of intrathecal injections and intravenous high-dose methotrexate. The risk repartition on the basis of the international prognostic index (IPI) of these 974 CR-patients was low (L): 41%, low-intermediate (LI): 27%, high-intermediate (HI): 19%, high (H): 13%. RESULTS The incidence of isolated CNS relapse was 1.6%. In a first multivariate logistic regression analysis an increased LDH (P = 0.05, RR = 5) and the presence of more than one extranodal site (P = 0.05, RR = 3) were identified as independent risk factors for isolated CNS relapse. Another multivariate analysis incorporating IPI as a unique parameter showed that only IPI remained significantly associated with a higher risk of CNS relapse (L-LI: 0.6% vs. HI H: 4.1%, P = 0.002; RR = 7). CONCLUSION Prophylaxis notably reduces the risk of CNS recurrence in the higher risk patients. By contrast, we propose the deletion of prophylactic intrathecal injections in the lower risk patients.
Collapse
Affiliation(s)
- C Haioun
- Hôpital Henri Mondor-AP-HP, Créteil, France. corinne.haioun@hmn-ap-hop-paris
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Judde JG, Lacoste V, Brière J, Kassa-Kelembho E, Clyti E, Couppié P, Buchrieser C, Tulliez M, Morvan J, Gessain A. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 2000; 92:729-36. [PMID: 10793109 DOI: 10.1093/jnci/92.9.729] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Infection with human herpesvirus 8 (HHV8), also termed Kaposi's sarcoma (KS)-associated herpesvirus, is associated with all forms of KS, with primary effusion lymphoma (PEL), and with some forms of multicentric Castleman's disease (MCD), but the pathogenic role of HHV8 in these tumors and the clonal nature of KS are still unclear. The purpose of this study was to examine whether the number of terminal repeats (TRs) contained in the fused TR region of HHV8 could be used as a marker of clonality in HHV8-associated tumors. METHODS Pulsed-field gel electrophoresis (PFGE) and multiple-probe Southern blot analysis of the HHV8 TR region were performed on high-molecular-weight DNA obtained from tumoral KS, PEL, and MCD lesions. RESULTS These analysis showed that the fused TR region contains a large but variable number of TR units (ranging from 16 to 75) and that the viral genome is present as extrachromosomal circular DNA in these tumors in vivo, with occasional ladders of heterogeneous linear termini reflecting lytic replication. All PEL tumors and PEL-derived cell lines as well as some KS tumors contained monoclonal or oligoclonal fused TR fragments; however, the TR region appeared polyclonal in MCD tumors and in a few KS lesions. CONCLUSION Several KS and PEL lesions are monoclonal expansions of a single infected cell, suggesting that HHV8 infection precedes tumor growth and thus supporting an etiologic role of latent HHV8 in these proliferations. Our finding that nodular KS lesions display all possible patterns of clonality supports the model according to which KS begins as a polyclonal disease with subsequent evolution to a monoclonal process.
Collapse
Affiliation(s)
- J G Judde
- Unité d'Oncologie Virale, Département des Rétrovirus, Institut Pasteur, Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|